Avectas partners with Vycellix to speed cell therapy production

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Robert Daly)
(Image: Getty/Robert Daly)

Related tags: Avectas, Vycellix, Cell engineering

The partners will combine expertise to progress the novel RNA immunomodulator, VY-M.

Avectas will provide access to its Solupure platform, which Vycellix will use to deliver its product candidate, VY-M, to T cells and NK cells.

According to Vycellix’s president, Douglas Calder, the use of Solupure will allow for the accelerated expansion time of T cells and NK cells by ‘decreasing the non-dividing lag times’ – the overall aim being to reduce the ‘vein-to-vein’ delivery time to patients.

In addition, the companies hope to reduce the cost of manufacture and to develop proprietary approaches for cell-based immunotherapeutic products.

Both companies are partners within NextGenNK, a center based on the development of NK cell-based cancer immunotherapies in Stockholm, Sweden.

The collaborative studies that will occur between the two partners will be divided between the Karolinska Institutet and Avectas’ Dublin, Ireland facility.

Vycellix willl use this platform to aid in the development of its pipeline of therapies, which includes VY-101 – a retargeted optimized NK cell therapy. The company hopes to be able to submit an investigational new drug filing in 2021 for the treatment candidate.

Avectas recently signed an agreement to also utilize the platform​ alongside the Centre for Commercialization of Regenerative Medicine to speed up the cell engineering process.

The company’s Solupure platform uses membrane disruption to deliver nucleic acids and proteins to cells rather than viral cell engineering.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

How Viral Safety Testing Will Evolve

How Viral Safety Testing Will Evolve

Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020 | Event Programme

The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space. Many of the methods used...

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Related suppliers

Follow us

Products

View more

Webinars